Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Phthalates exposure indicators determined by urinary phthalate metabolites in healthy non-obese Czech adults: FANTOM study.

Müllerová D, Bouchalová V, Matějková D, Kovářová K, Svačina Š, Vrbík K, Pavloušková J, Dvořáková J, Müller L.

Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2016 Dec;33(12):1817-1825.

PMID:
27689474
2.

PERSISTENT ORGANOCHLORINE POLLUTANTS IN OBESE WOMEN AFTER DIET INDUCED WEIGHT LOSS: FIVE YEARS FOLLOW UP STUDY.

Müllerová D, Matějková D, Dvořáková J, Müller L, Rosmus J, Kovářová K.

Cent Eur J Public Health. 2015 Sep;23(3):214-7.

3.

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Hokusai-VTE Investigators., Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P.

N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Erratum in: N Engl J Med. 2014 Jan 23;370(4):390.

4.

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

EINSTEIN–PE Investigators., Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A.

N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572.

5.

Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.

Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI; ADOPT Trial Investigators..

N Engl J Med. 2011 Dec 8;365(23):2167-77. doi: 10.1056/NEJMoa1110899.

6.

Oral rivaroxaban for symptomatic venous thromboembolism.

EINSTEIN Investigators., Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S.

N Engl J Med. 2010 Dec 23;363(26):2499-510. doi: 10.1056/NEJMoa1007903.

7.

Dabigatran versus warfarin in patients with atrial fibrillation.

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators..

N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877.

8.

[Bioelectical impedance analysis for comparison of the body composition in type 1 diabetes patients, obese patients and healthy volunteers].

Baxová L, Zourek M, Frantová V, Kovárová K, Rusavý Z.

Vnitr Lek. 2009 May;55(5):462-7. Czech.

PMID:
19514611
9.

Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.

Botticelli Investigators, Writing Committe., Buller H, Deitchman D, Prins M, Segers A.

J Thromb Haemost. 2008 Aug;6(8):1313-8. doi: 10.1111/j.1538-7836.2008.03054.x.

10.

[Comparison of dietary habits in obese and thin women using the food frequency questionnaire].

Müllerová D, Matĕjková D, Brázdová Z, Kovárová K.

Sb Lek. 2002;103(4):495-8. Czech.

PMID:
12688164
11.
12.

Cultivation of Escherichia coli with mixtures of 3-phenylpropionic acid and glucose: steady-state growth kinetics.

Kovárová K, Käch A, Zehnder AJ, Egli T.

Appl Environ Microbiol. 1997 Jul;63(7):2619-24.

13.
14.

Supplemental Content

Loading ...
Support Center